培哚普利对慢性心力衰竭患者血浆t-PA和PAI-1水平的影响

Effects of peidolapril on plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with chronic heart failure

目的：评价培哚普利对慢性心力衰竭（CHF）患者血浆组织型纤溶酶原激活物（t—PA）和纤溶酶原激活物抑制物-1（PAI-1）水平的影响。方法：采用酶联免疫吸附法测定60例CHF患者（CHF组）及20例健康人（正常对照组）血浆t—PA、PAI-1水平。CHF组患者又随机均分为常规治疗亚组和培哚普利亚组。培哚普利亚组在常规治疗基础上加用培哚普利2～4mg，每日1次。所有CHF患者治疗2周后复测血浆t—PA、PAI-1水平。结果：CHF患者血浆t-PA、PAI-1水平比正常对照组明显增高（P〈0．01）。治疗后，培哚普利亚组血浆PAI-1水平比常规治疗亚组明显降低（P〈0．01），血浆t—PA水平比常规治疗亚组明显升高（P〈0．01）。结论：培哚普利不仅可降低PAI-1水平，而且可升高t—PA水平，改善内源性纤溶功能。

Objective：To evaluate the effects of peidolapril on plasma tissue plasminogen activator （t-PA） and plasminogen activator inhibitor-1 （PAI-1） in patients with chronic heart failure （CHF）. Method：The levels of plasma t-PA and PAI-1 were detected in sixty patients with CHF and twenty normal controls by enzyme-linked immunosorbent assay. Sixty patients with CHF were randomized to receive peidolapril 2-4 mg daily besides conventional therapy （n：30） or only conventional therapy （n：30） for two weeks. The levels of plasma t-PA and PAI-1 were detected after treatment. Result：Compared with the normal controls, the levels of plasma t-PA and PAI-1 in patients with CHF were significantly increased （P〈0.01）. Administration of peidolapril was associated with the levels of significant decrease of plasma PAI-1 （P〈0.01） and increase of t-PA （P〈0.01）. Conelusion：Peidolapril could improve fibrinolytic function of patients with CHF by decreasing plasma PAI-1 and increasing plasma t-PA levels.